Abbott Laboratories: Analyst Ratings and Growth Prospects in MedTech and Non-MedTech

Tuesday, 8 October 2024, 08:59

Abbott Laboratories is witnessing bullish analyst ratings, particularly around MedTech and non-MedTech sectors. The company anticipates revenue growth driven by margin expansion in Nutrition and Diagnostics. As Abbott (NYSE:ABT) navigates these trends, a closer look reveals potential upward trajectories in its markets.
Benzinga
Abbott Laboratories: Analyst Ratings and Growth Prospects in MedTech and Non-MedTech

Abbott Laboratories: Analyst Ratings

Abbott Laboratories has captured the attention of analysts amid promising forecasts for both MedTech and non-MedTech segments. Recent insights indicate that Nutrition and Diagnostics revenues are set to experience easing over the next few years. This trajectory suggests a robust outlook with revenue growth predicted to be accompanied by margin expansion of 30 to 50 basis points annually through fiscal 2026.

Growth Drivers in MedTech

  • Strength in cardiovascular devices.
  • Innovations in diabetes care technologies.

Non-MedTech Insights

On the non-MedTech front, slowing comps could positively affect overall financial performance, allowing for reinvestment back into core business segments.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe